Clinical Trials

RTOG 0424: A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas


  • Brief Overview:

    Eligible patients will undergo radiation therapy along with oral temozolomide chemotherapy followed by chemotherapy alone.

  • Inclusion Criteria

    • Histological proof of a unifocal or multifocal supratentorial WHO grade II astrocytoma (diffuse fibrillary, protoplasmic, or gemistocytic), oligodendroglioma, or oligoastrocytoma
    • Patient must have at least three of the following risk factors:
      • Age greater than or equal to 40 years
      • Largest preoperative diameter of tumor greater than 6 cm
      • Tumor crosses midline of brain
      • Tumor subtype of astrocytoma (astrocytoma dominant)
      • Preoperative Neurological function status greater than 1

  • Exclusion Criteria

    • Prior chemotherapy
    • Prior radiation to the brain or head/neck
    • Known HIV infection
    • Active infectious process

  • For more information, contact Dr. Paul Okunieff at 585-273-4096


  • View all Clinical Trials